chronic pain syndromes Complex Regional Pain Syndrome type I (CRPS-I) and chronic pain
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: for CRPS-I patients: - Diagnosis of Complex Regional Pain Syndrome Type I - Unilateral localization on upper extremity;for LBP patients: - Experience of non-specific low back pain for at least three months - No other diagnosis better explaining the signs and symptoms;all patients: - Stable medication - Substantial fear of movement/(re)-injury;for all patients and healthy controls: - Age between 18 and 65 years old
Exclusion criteria
Exclusion criteria: for patients and healthy controls: - peripheral neuropathy of upper extremity - magnetic resonance imaging incompatible health condition - psychopathology (according to SCL 90) - tactile sensitivity impairment as a result of cranial, spinal lesion or damage of sensory apparatus for healthy controls only: - (history of) CRPS or other chronic pain syndromes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patients and healthy controls: 1) Blood-oxygenation level dependent response (BOLD signal), during rest, during the tactile stimulations and during watching of pictures that might be experienced as threatful by the patients. 2) Tactile discrimination threshold in mm (minimal offset in dot pattern required for reliable discrimination [>80%] of the directionality of this offset)(CRPS-I) / Performance on lifting task (LBP) 3) Fractional anisotropy of water diffusivity. | — |
Secondary
| Measure | Time frame |
|---|---|
| patients and healthy controls: - Pain feedback during MRI session - Handedness as measured by the Edinburgh handedness inventory. - Physical activity in daily life measured during 7 days around the pre and post measurement with the Actiwatch motion sensor (Cambridge Neurotechnology Ltd., Cambridge, UK) on the left and right arm. - Fear of movement, measured by three standard questionnaires : the Tampa Scale for Kinesiophobia, the Photograph series of daily activities for the upper extremities (PHODA-UE), the Pain Anxiety Symptoms Scale (PASS-20). - Catastrophic thinking, measured by the Pain Catastrophizing Scale. - Bodily structure and function, measured by: 1. the Neuropathic Pain Scale; 2. the McGill Pain Questionnaire Dutch version (MPQ-DLV); 3. Aβ-fibre mediated allodynia for the upper extremities. 4. Vasomotoric symptoms: temperature differences; 5. Sudomotoric symptoms: edema. patients only: - Dairy measurements of the symptoms measured by some items from the above mentioned questionnaires. Other parameters patients and healthy controls: - Demographic characteristics patients only: - Illness-related facts (duration, localisation etc.) - Compliance and involvement, as indicated by treatment session attendance and completed diary entries. | — |
Countries
Netherlands